Ph2 trials are typically done to assess efficacy AND safety. Usually in that order.
Ph1 defines safety, typically in a small cohort.
Ph2 explores efficacy and safety in a larger group.
Ph3 studies efficacy in a larger group again.
Ph4 is typically done post-marketing.
I am expecting the primary outcome to be met, and anything over and above 15% decrease in proteinuria to meet clinicalsignificance. That would warrant a Ph3.
Depends upon how the company releases it. If all patients show a 20% decrease? Or half of them show a 40% decrease and the remainder show a 10% decrease? Stats was never my strong suit.
And a Ph3 company in a FDA-designated orphan disease.... you can figure out the rest...
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
Ann: Quarterly Appendix 4C and Activities Report, page-209
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
42.0¢ |
Change
-0.025(5.62%) |
Mkt cap ! $231.2M |
Open | High | Low | Value | Volume |
43.5¢ | 44.0¢ | 41.8¢ | $1.239M | 2.905M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 257588 | 42.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.5¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 0.420 |
5 | 140871 | 0.415 |
9 | 112924 | 0.410 |
4 | 97555 | 0.405 |
13 | 124652 | 0.400 |
Price($) | Vol. | No. |
---|---|---|
0.425 | 10000 | 1 |
0.430 | 107896 | 3 |
0.440 | 20000 | 1 |
0.445 | 100000 | 1 |
0.450 | 83817 | 4 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
DXB (ASX) Chart |